Chief Executive Officer
Pieter has 24 years of experience in listed and non-listed equities in Central Europe, United States and the CIS and an outstanding track record of investment banking within the biotech sector. During the mid-1990s he was with Nomura International in London, a dominant securities house with a substantial in-house trading book. He headed up the Sales Desk of the Healthcare and Technology Group, which was one of the most profitable in-house groups of Nomura at the time.
Having gained extensive experience of complex corporate finance transactions, it was a natural progression for him to set up Mulier Capital in 2002. To date he has transacted deals with an aggregate value of over 3 billion US$. He has an in-depth knowledge of transactions in all asset classes and has managed / syndicated these transactions from sourcing to closing.
He holds the rank of reserve Lt-Col in the Netherlands cavalry, Huzaren van Boreel.
Chief Commercial Officer
Alex was educated at Bradfield College as a Moulsdale Scholar, the London School of Economics and the University of British Columbia. Starting his career in the International Capital Markets at Tokai Bank, then a top ten bank by balance sheet, he was Head of Middle East Distribution for fixed income and traded the AUD/CDN/NZD books.
In 1998 his investment management consultancy firm was merged into LAI International, a NASDAQ listed enterprise. Later he was approached to effect a turn-round, becoming co-managing partner of RKA. It blossomed into an EIU award winning professional services business, encompassing corporate advisory, human capital and market leading competitive intelligence offerings to some of the world’s largest financial services firms, including Goldman Sachs, Deutsche Bank and Dresdner Kleinwort Benson.
Chief Finance Officer
Adam was instrumental in the initial funding of the company and continues to oversee its financial and investor related matters.
Over the last 25 years, Adam has grown his practice into a thriving Group of businesses that acts for High Net Worth individuals and SMEs. Over the last 10 years in particular, Adam has assisted several SMEs in their formative stages by providing fund raising capability, structuring expertise and advice on taxation and exit planning.
Dr Stephen Minter PhD
Chief Scientist & Inventor
Stephen has a demonstrable track record of invention and innovation in the biotechnology sector and he has filed circa 70 patents over the last 30 years. He founded Tepnel Diagnostics Ltd in 1982 with Terry Colley and in 1992 shares in Tepnel Diagnostics were made available on the London Stock Exchange with an initial market capitalisation of over £80m. Tepnel Life Sciences was later sold to GenProbe Corporation in 2010 for $155 million.
In 2006 Stephen was invited to take on the role of Chief Technical Officer and Director of the National Nanotechnology Centre for Food and Pharmaceuticals a wholly owned subsidiary of Nottingham University. In that capacity he invented and patented a new form of crystalline salt that was designed to allow a reduction of salt levels in foods by up to 30% without reducing the flavour or shelf life of the foodstuff. This technology can be widely used in foods allowing companies to meet the European guide lines on food standards.
Dr Georgios Patsos
Deputy Chief Scientific Officer & Inventor
Georgios completed his postgraduate studies in Virology/Immunology and was awarded an MSc from Manchester University, and a PhD from Bristol University. He continued his research examining the effect of glycosylation inhibitor molecules on cancer cell growth at Bristol University. He then moved to Heidelberg University on a Marie-Curie fellowship where he focused on the application of plant proteins as glycodiagnostic tools for cancer, producing several publications in this area.
He then furthered his post-doctoral experience in more market orientated projects. Firstly, at Liege University were he worked on the in silico identification of cancer vaccine targets on behalf of GlaxoSmithKline Biologicals Ltd. Secondly, at the National University of Ireland, Galway, working on the development of glycan specific molecular diagnostic tools. During his post-doctoral posts he became an expert in cancer glycoscience and glycodiagnostics. His diagnostic work and diverse experience were the ideal stepping stones into the biotech sector, where Georgios is an inventor for RevoluGen’s technologies. More recently, Georgios invented a novel nucleic acid amplification and sequence detection method ‘Fire Wolf‘.
Dr Erling Refsum
Erling Refsum trained in medicine at Guys Hospital and then worked in the NHS for 9 years becoming a Fellow of the Royal College of Surgeons of Edinburgh in 1983. He subsequently joined the Nomura Research Institute in 1987 and became the head of the Lifesciences Equities Research Team being voted the number one biotechnology and healthcare analyst by the Reuters UK smaller company survey for 3 years running between 1999 and 2001. Whilst at Nomura, he won the first Hungarian Privatisation Round for Gideon Richter, was key to gaining 25 biotech corporate clients and generated over a 100% return on a £50m Biotech Bottom Fishing Book.
Since leaving Nomura in late 2005 he has predominantly worked at finding finance for small biotech companies at Mulier Capital and Eden Corporate Finance, raising over $60m for clients.
Dr Ann Simon
Dr. Ann Simon has worked in finance, particularly in the life sciences and technology sectors, since 1985. She is a non-executive director of AIM-listed Scientific Digital Imaging, Spectrum (General Partner) and Lumacron and also provides consultancy in the areas of finance, strategic planning, enablement and funding.
Over the past 15 years she has held executive roles as CFO of a number of companies including Pyreos, mLED, Sphere Medical and Genosis, Prior to that she undertook corporate finance advisory work at Cazenove & Co for over a decade for clients ranging from start-ups to FTSE100 companies. She has managed IPOs (London full list and AIM), corporate acquisitions and trade sales and fund raisings in the public and private markets. She was on the FSA’s Financial Information Theme Team 2002-3.
Ann has a PhD in physics and completed 10 years of postgraduate work mainly at the Cavendish Laboratory, Cambridge with periods spent in Germany, France and the USA.
Simon Davenport QC
Simon Davenport QC of 3 Hare Court, practices in Insolvency, Civil Fraud and Commercial dispute resolution including Arbitration cases.
He is head of all of the chambers groups in these areas and is widely acclaimed as a leading silk in these fields across the Bar, being named as a Leading Silk in the Legal 500 in Civil Fraud, Insolvency and Commercial Litigation.
Simon has been appointed to the Serious Fraud Office approved list of Queen’s Counsel and in 2011 he was appointed to the Treasury Solicitors’ panel of Queen’s Counsel. He is a member of both the Policy Group and the Fraud Group of R3 (the leading insolvency recovery professional body). In 2015, Simon was elected as a bencher of the Honorable Society of the Inner Temple.
Director & Investor
Martin St Quinton (60) was born in Yorkshire. He graduated from Durham University in 1979 and went on to obtain his MBA in the USA.
In 1980 he started The Saint Group a private office equipment company which was sold to Danka plc in 1993. From then until 1999 he was CEO of Danka’s International Operations. During this six-year period he acquired over 50 companies in 30 different countries. Danka grew to be the world’s second largest photocopier company with sales in excess of £1bn.
In 2000, he founded another company Azzurri Communications, a UK based Voice & Data Integrator, which grew to 700 staff and £150m turnover in 6 years. In 2006 Azzurri was sold for £180m to The Prudential Group. In recognition of his achievements at Azzurri Martin was named Ernst & Young Entrepreneur of the Year in 2003.
In a 30 year career he has acquired over 70 companies and integrated these businesses to create two groups of companies both of which were subsequently sold.
Martin is currently a Non Executive Director of 6 other companies including Gloucester Rugby Club where he is Chairman. He lives in Hampshire with his wife and 4 children.
Greg Healey is an Associate of The Institute of Chartered Accountants in England and Wales having trained with PricewaterhouseCoopers, he subsequently joined the mergers and acquisitions team with Lazard investment bank where as a Vice President in the Technology group successfully completed a vast array of public and private transactions.
Since leaving Lazard in 2011 Greg has founded a number of successful businesses and currently actively manages a portfolio of over 30 business investments.